Core Viewpoint - The company, Yong'an Pharmaceutical (002365.SZ), has clarified that it does not currently develop or produce the drug Liraglutide, which has been inquired about for its potential use in weight loss and diabetes treatment [2][4]. Group 1: Company Operations - Yong'an Pharmaceutical primarily engages in three business areas: research, production, and sales of taurine products; research, production, and sales of health foods; and research, production, and sales of special dietary foods (creatine) [2][4]. - The company has not developed or produced Liraglutide products as of the latest update [2][4].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is primarily engaged in three business segments: the research, production, and sales of taurine products; the research, production, and sales of health foods; and the research, production, and sales of special dietary foods (creatine) [1] Business Segments - The company focuses on the development, production, and sales of taurine products [1] - The company also engages in the research, production, and sales of health foods [1] - Additionally, the company is involved in the research, production, and sales of special dietary foods, specifically creatine [1] - Currently, the company has not commenced the production or research of limonamide products [1]